Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real‐world setting in China

Documenti analoghi

• Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study
  di: Weijun Gu, et al.
  Pubblicazione: (2025)
• The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
  di: Ming Liu, et al.
  Pubblicazione: (2024)
• Evaluation of efficacy of iGlarLixi versus IDegAsp using derived time‐in‐ranges in Chinese adults with Type 2 diabetes: A post hoc analysis of the Soli‐D study
  di: Juan Liu, et al.
  Pubblicazione: (2025)
• The association between glycaemic control, normal weight and long‐term macrovascular outcomes in people with type 2 diabetes in China: A retrospective study
  di: Feng Sun, et al.
  Pubblicazione: (2025)
• IDegLira for the real‐world treatment of type 2 diabetes in Italy. Final results from the REX observational study
  di: Gian Paolo Fadini, et al.
  Pubblicazione: (2024)